Nevertheless, other clinical trials were approved to evaluate nicotinamide’s effect on tau levels in CSF of AD patients during a 48-week period (Clinical trials: NCT03061474), but no results have been published so far. The gene discussed is MAPT; the disease is Alzheimer disease.